![Peter Radovich](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Radovich
President chez
MIRUM PHARMACEUTICALS, INC.
Fortune : 6 M $ au 31/05/2026
Profil
Peter Radovich is President & Chief Operating Officer at Mirum Pharmaceuticals, Inc. since 2024, with employment at the firm starting in 2020.
Former roles include Independent Director at Rain Oncology, Inc. from 2018 to 2024; Senior Vice President-Operations at Global Blood Therapeutics, Inc. from 2016 to 2020; Vice President-Global Product Kyprolis at Onyx Pharmaceuticals, Inc. from 2013 to 2014; Senior Director & VP-Program Leadership at Onyx Pharmaceuticals, Inc. from 2004 to 2006; and Principal at Chiron Corp.
from 2004 to 2006.
Education includes an MBA from the University of Washington and undergraduate studies at Texas Christian University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/06/2026 | 57 260 ( 0,09 % ) | 6 M $ | 31/05/2026 |
Postes actifs de Peter Radovich
| Sociétés | Poste | Début |
|---|---|---|
| MIRUM PHARMACEUTICALS, INC. | President | 16/01/2024 |
Anciens postes connus de Peter Radovich
| Sociétés | Poste | Fin |
|---|---|---|
| RAIN ONCOLOGY INC. | Directeur/Membre du Conseil | 25/01/2024 |
| GLOBAL BLOOD THERAPEUTICS, INC. | Directeur des opérations | 01/04/2020 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Corporate Officer/Principal | 01/01/2014 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Directeur/Membre du Conseil | 01/09/2006 |
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Corporate Officer/Principal | 01/01/2006 |
Formation de Peter Radovich
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
67
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Texas Christian University
 Texas Christian University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides treatment and care of sickle cell disease for inherited blood disorder | Health Technology |
Rain Oncology, Inc.
 Rain Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage precision oncology company that develops therapeutics for cancer patients | Health Technology |
Mirum Pharmaceuticals, Inc.
 Mirum Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage therapeutics company developing a novel approach for treating cholestasis liver diseases | Health Technology |
